Xintong Medical-B (02160) establishes a strategic committee and commercialization committee

Zhitong Finance App News, Xintong Medical-B (02160) issued an announcement, effective December 15, 2025: Mr. Chen Guoming, a non-executive director and chairman of the board of directors, has been appointed as a member of the Audit Committee and is no longer a member of the Remuneration Committee and Chairman of the Nomination Committee. Dr. Hu Bingshan, an independent non-executive director, has been re-appointed as Chairman of the Nomination Committee, has been appointed as a member of the Remuneration Committee, and is no longer a member of the Audit Committee. Dr. Brian Chang, a non-executive director, has been appointed as a member of the Nomination Committee.

The Board of Directors resolved to establish a Strategy Committee under the Board of Directors, which will take effect on December 15, 2025. The Strategy Committee was established to study and make suggestions on the company's long-term development strategy and major development decisions. The Strategy Committee consists of six members, including Dr. Brian Chang, Mr. Chen Guoming, Mr. Zhang Ruinian, Mr. Philippe Wanstok, Mr. Deng Aoyi, and Dr. Hu Bingshan. Dr. Brian Chang is the chairman.

Furthermore, the board of directors resolved to establish a commercialization committee under the board of directors, which will take effect on December 15, 2025. The purpose of establishing a commercialization committee is to further optimize the planning and implementation of the company's commercialization system, give full play to the guiding role of the commercialization committee, and effectively enhance the competitive advantage of the company's products in the commercialization stage. The Commercialization Committee consists of five members, namely Mr. Chen Guoming, Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok, and Ms. Wu Xia. Mr. Chen Guoming is the chairman.